Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10259835 Alvocidib prodrugs having increased bioavailability

Patent 10259835 was granted and assigned to Tolero Pharmaceuticals on April, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Tolero Pharmaceuticals

0

Current Assignee

Tolero Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

David J. Bearss0

Adam Siddiqui-Jain0

Date of Patent

April 16, 2019

0

Patent Application Number

156732130

Date Filed

August 9, 2017

0

Patent Citations Received

US Patent 12077554 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

0

US Patent 11034710 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

US Patent 11279694 Alvocidib prodrugs and their use as protein kinase inhibitors

US Patent 11883260 Delivery apparatus, system and associated methods

0

US Patent 11957542 Sensing complete injection for animal injection device

0

US Patent 11497756 Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib

US Patent 10422788 Profiling peptides and methods for sensitivity profiling

US Patent 10562925 Alvocidib prodrugs having increased bioavailability

...

Patent Primary Examiner

Kevin E. Weddington

0

Patent abstract

Compounds having the following structure (I):

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10259835 Alvocidib prodrugs having increased bioavailability

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool